NASDAQ:ALNY Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis $294.36 -0.51 (-0.17%) (As of 03:44 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$293.58▼$301.0550-Day Range$246.78▼$300.5552-Week Range$141.98▼$304.39Volume420,557 shsAverage Volume867,426 shsMarket Capitalization$37.23 billionP/E RatioN/ADividend YieldN/APrice Target$290.86Consensus RatingModerate Buy Company OverviewAlnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Read More… Kickstart your own Weekend Side Hustle right from your couch (Ad)Today I want to show you how to start your very own Weekend Side Hustle right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.Click here & let me show you how I am targeting extra income as early as THIS weekend! Alnylam Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks76th Percentile Overall ScoreALNY MarketRank™: Alnylam Pharmaceuticals scored higher than 76% of companies evaluated by MarketBeat, and ranked 281st out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 18 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alnylam Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($2.73) to ($2.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is -489.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is -489.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Alnylam Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.57% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently increased by 1.35%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.52 Percentage of Shares Shorted3.57% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently increased by 1.35%, indicating that investor sentiment is decreasing. News and Social Media3.0 / 5News Sentiment0.34 News SentimentAlnylam Pharmaceuticals has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Alnylam Pharmaceuticals this week, compared to 10 articles on an average week.Search Interest6 people have searched for ALNY on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows6 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,595,460.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Alnylam Pharmaceuticals is held by insiders.Percentage Held by Institutions92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alnylam Pharmaceuticals' insider trading history. ALNY Stock News HeadlinesAscendis Pharma’s Promising Pipeline: Buy Rating Backed by TransCon CNP’s Potential Market Leadership and Yorvipath’s Broad US LabelOctober 24 at 11:28 AM | markets.businessinsider.comBarclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)October 22 at 6:38 AM | markets.businessinsider.comKickstart your own Weekend Side Hustle right from your couch Today I want to show you how to start your very own Weekend Side Hustle right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.October 24, 2024 | DTI (Ad)Alnylam price target raised to $371 from $282 at TD CowenOctober 22 at 6:38 AM | markets.businessinsider.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Average Rating of "Moderate Buy" by AnalystsOctober 22 at 5:08 AM | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Given New $371.00 Price Target at TD CowenOctober 22 at 4:15 AM | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Receives "Buy" Rating from HC WainwrightOctober 22 at 1:31 AM | americanbankingnews.comScotiabank Begins Coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY)October 19, 2024 | americanbankingnews.comSee More Headlines ALNY Stock Analysis - Frequently Asked Questions How have ALNY shares performed this year? Alnylam Pharmaceuticals' stock was trading at $191.41 at the beginning of 2024. Since then, ALNY stock has increased by 53.6% and is now trading at $293.96. View the best growth stocks for 2024 here. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.61. The business's quarterly revenue was up 107.0% compared to the same quarter last year. Who are Alnylam Pharmaceuticals' major shareholders? Top institutional shareholders of Alnylam Pharmaceuticals include DekaBank Deutsche Girozentrale (0.09%), Handelsbanken Fonder AB (0.06%), Swedbank AB (0.04%) and Forsta AP Fonden (0.04%). Insiders that own company stock include Yvonne Greenstreet, Jeffrey V Poulton, Akshay Vaishnaw, Michael W Bonney, Pushkal Garg, Kevin Joseph Fitzgerald, Amy W Schulman, Tolga Tanguler, Steven M Paul, Dennis A Ausiello, David E I Pyott, Indrani Lall Franchini and John Maraganore. View institutional ownership trends. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alnylam Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), AUO (AUOTY), DiamondRock Hospitality (DRH) and The RMR Group (RMR). Company Calendar Last Earnings8/01/2024Today10/24/2024Next Earnings (Confirmed)10/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALNY CUSIP02043Q10 CIK1178670 Webwww.alnylam.com Phone(617) 551-8200Fax617-551-8101Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$290.86 High Stock Price Target$400.00 Low Stock Price Target$159.00 Potential Upside/Downside-1.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage24 Analysts Profitability EPS (Most Recent Fiscal Year)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-440,240,000.00 Net Margins-3.11% Pretax Margin-2.63% Return on EquityN/A Return on Assets-1.88% Debt Debt-to-Equity RatioN/A Current Ratio3.01 Quick Ratio2.93 Sales & Book Value Annual Sales$2.34 billion Price / Sales15.86 Cash FlowN/A Price / Cash FlowN/A Book Value($1.76) per share Price / Book-167.02Miscellaneous Outstanding Shares126,492,000Free Float126,455,000Market Cap$37.18 billion OptionableOptionable Beta0.39 Social Links This page (NASDAQ:ALNY) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredAre You Holding the Winning Hand in the Copper Market?Are You Holding the Winning Hand in the Copper Market?Market JAR | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredNext opportunity for crypto millionsAccording to Steven Lubka, head of a private equity firm with over $250M in assets under management, "Bitcoin ...Crypto 101 Media | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.